Hematologic Complications of Immune Checkpoint Inhibitors

Elizabeth J Davis, Joe-Elie Salem, Arissa Young, Jennifer R Green, P Brent Ferrell, Kristin K Ancell, Benedicte Lebrun-Vignes, Javid J Moslehi, Douglas B Johnson, Elizabeth J Davis, Joe-Elie Salem, Arissa Young, Jennifer R Green, P Brent Ferrell, Kristin K Ancell, Benedicte Lebrun-Vignes, Javid J Moslehi, Douglas B Johnson

Abstract

Immune checkpoint inhibitors have improved outcomes for patients with numerous hematological and solid cancers. Hematologic toxicities have been described, but the spectrum, timing, and clinical presentation of these complications are not well understood. We used the World Health Organization's pharmacovigilance database of individual-case-safety-reports (ICSRs) of adverse drug reactions, VigiBase, to identify cases of hematologic toxicities complicating immune checkpoint inhibitor therapy. We identified 168 ICSRs of immune thrombocytopenic purpura (ITP), hemolytic anemia (HA), hemophagocytic lymphohistiocytosis, aplastic anemia, and pure red cell aplasia in 164 ICSRs. ITP (n = 68) and HA (n = 57) were the most common of these toxicities and occurred concomitantly in four patients. These events occurred early on treatment (median 40 days) and were associated with fatal outcome in 12% of cases. Ipilimumab-based therapy (monotherapy or combination with anti-programmed death-1 [PD-1]) was associated with earlier onset (median 23 vs. 47.5 days, p = .006) than anti-PD-1/programmed death ligand-1 monotherapy. Reporting of hematologic toxicities has increased over the past 2 years (98 cases between January 2017 and March 2018 vs. 70 cases before 2017), possibly because of increased use of checkpoint inhibitors and improved recognition of toxicities. Future studies should evaluate incidence of hematologic toxicities, elucidate risk factors, and determine the most effective treatment algorithms. KEY POINTS: Immune-mediated hematologic toxicities are a potential side effect of immune checkpoint inhibitors (ICIs).Providers should monitor complete blood counts during treatment with ICIs.Corticosteroids are the mainstay of treatment for immune-mediated hematologic toxicities.Further research is needed to define patient-specific risk factors and optimal management strategies for hematologic toxicities.

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

© AlphaMed Press 2019.

Figures

Figure 1.
Figure 1.
Number of cases of hematologic toxicity by time on therapy. Time to development of toxicity based upon hematologic toxicity. Abbreviations: HA, hemolytic anemia; HLH, hemophagocytic lymphohistiocytosis; ITP, immune thrombocytopenic purpura.
Figure 2.
Figure 2.
Time to development of hematologic toxicity by therapy. Time to development of toxicity related to anti‐cytotoxic T lymphocyte antigen‐4 (CTLA‐4)‐based therapy (either monotherapy or in combination with anti‐programmed death‐1 [PD‐1]) versus anti‐PD‐1/programmed death ligand‐1 inhibitors. Red line: CTLA‐4; Blue line: PD‐1.
Figure 3.
Figure 3.
Reporting year of hematologic toxicity. Dark blue: hemophagocytic lymphohistiocytosis; Red: aplastic anemia; Green: hemolytic anemia; Purple: immune thrombocytopenic purpura; Light blue: pure red cell aplasia.

References

    1. Kong BY, Micklethwaite KP, Swaminathan S et al. Autoimmune hemolytic anemia induced by anti‐PD‐1 therapy in metastatic melanoma. Melanoma Res 2016;26:202–204.
    1. Nair R, Gheith S, Nair SG. Immunotherapy‐associated hemolytic anemia with pure red‐cell aplasia. N Engl J Med 2016;374:1096–1097.
    1. Palla AR, Kennedy D, Mosharraf H et al. Autoimmune hemolytic anemia as a complication of nivolumab therapy. Case Rep Oncol 2016;9:691–697.
    1. Schwab KS, Heine A, Weimann T et al. Development of hemolytic anemia in a nivolumab‐treated patient with refractory metastatic squamous cell skin cancer and chronic lymphatic leukemia. Case Rep Oncol 2016;9:373–378.
    1. Tardy MP, Gastaud L, Boscagli A et al. Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report. Hematol Oncol 2017;35:875–877.
    1. Shiuan E, Beckermann KE, Ozgun A et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy. J Immunother Cancer 2017;5:8.
    1. Lindquist M. VigiBase, the WHO global ICSR database system: Basic facts. Ther Innov Regul Sci 2008;42:409–419.
    1. Satzger I, Ivanyi P, Langer F et al. Treatment‐related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer 2018;93:150–153.
    1. Malissen N, Lacotte J, Du‐Thanh A et al. Macrophage activation syndrome: A new complication of checkpoint inhibitors. Eur J Cancer 2017;77:88–89.
    1. Shah D, Shrestha R, Ramlal R et al. Pembrolizumab associated hemophagocytic lymphohistiocytosis. Ann Oncol 2017;28:1403.
    1. Ammann S, Lehmberg K, Zur Stadt U et al. Primary and secondary hemophagocytic lymphohistiocytosis have different patterns of T‐cell activation, differentiation and repertoire. Eur J Immunol 2017;47:364–373.
    1. Hosokawa K, Muranski P, Feng X et al. Memory stem T cells in autoimmune disease: High frequency of circulating CD8+ memory stem cells in acquired aplastic anemia. J Immunol 2016;196:1568–1578.
    1. Hollinger MK, Giudice V, Cummings NA et al. PD‐1 deficiency augments bone marrow failure in a minor‐histocompatibility antigen mismatch lymphocyte infusion model. Exp Hematol 2018;62:17–23.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera